We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

11 hedge funds and large institutions have $482K invested in Northwest Biotherapeutics, Inc. Common stock in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 11 → 11 (0)

71% less capital invested

Capital invested by funds: $1.69M → $482K (-$1.21M)

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MSAM
Moloney Securities Asset Management
Missouri
+$20.9K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
MSAM
1
Moloney Securities Asset Management
Missouri
$321K +$20.9K +23,000 +7%
OCG
2
Opus Capital Group
Ohio
$55K – – –
WJWM
3
Williams Jones Wealth Management
New York
$40K – – –
MCM
4
MAI Capital Management
Ohio
$18.2K – – –
LDB
5
Lee, Danner & Bass
Tennessee
$18K – – –
AA
6
AlphaMark Advisors
Kentucky
$13K – – –
AMG
7
Advisors Management Group
Wisconsin
$9K – – –
BC
8
Bartlett & Co
Ohio
$4K – – –
BCWM
9
Bartlett & Co Wealth Management
Ohio
$3.9K – – –

NWBO Hedge Fund Activity: Q3 2023 in Review

11 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2023, worth a combined $482K — down 71% from $1.69M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new NWBO positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Moloney Securities Asset Management, adding an estimated $20.9K.

  • 11 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $482K of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2023, down 71% quarter-over-quarter.
  • 1 fund opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2023 and 0 closed out, a net change of +1 holder.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2023 was Moloney Securities Asset Management, an estimated $20.9K added.

Based on aggregated 13F filings for Q3 2023.